Hermetica Superfood Encyclopedia
The Short Answer
Methylselenocysteine is metabolized by mammalian β-lyase enzymes to methylselenol (CH₃SeH), a reactive selenium metabolite that exerts chemopreventive and antioxidant effects without significant tissue accumulation or incorporation into body proteins. In a randomized double-blind trial in selenium-replete men (n=29, baseline plasma Se ~108 µg/L), supplementation with 400–800 µg Se/day as SeMSC for 84 days raised plasma selenium significantly at 400 µg/day but, unlike selenomethionine, produced no progressive long-term accumulation, supporting a safer pharmacokinetic profile at supranutritional doses.
CategoryMineral
GroupMineral
Evidence LevelPreliminary
Primary Keywordmethylselenocysteine benefits
Methylselenocysteine — botanical close-up
Health Benefits
**Chemopreventive Activity via Methylselenol Generation**
SeMSC is uniquely metabolized by β-lyase to methylselenol (CH₃SeH), a reactive selenium species demonstrated in preclinical models to inhibit cancer cell proliferation, induce apoptosis, and suppress angiogenesis without the toxicity associated with inorganic selenium forms.
**Efficient Selenoprotein Support Without Protein Incorporation**: Unlike selenomethionine, SeMSC is fully bioavailable for selenoenzyme synthesis (e.g., glutathione peroxidase, thioredoxin reductase) without being non-specifically incorporated into albumin or structural proteins, making it a metabolically cleaner selenium donor at physiological doses.
**Antioxidant Defense Enhancement**
By supporting glutathione peroxidase (GPx) activity, SeMSC contributes to cellular defense against oxidative stress and lipid peroxidation, key mechanisms in cardiovascular and cancer protection; GPx upregulation is a direct downstream consequence of selenium bioavailability from this pathway.
**Low Accumulation Safety Profile at Supranutritional Doses**: Clinical pharmacokinetic data demonstrate that SeMSC at 800 µg Se/day for 84 days in selenium-replete subjects does not produce the progressive plasma selenium accumulation seen with selenomethionine, reducing the risk of selenosis during supplementation at 5–10 times the recommended dietary intake.
**Selenoprotein P (SEPP1) Modulation**
In selenium-replete individuals, SeMSC at 800 µg/day produced a transient peak increase in selenoprotein P (SEPP1) on day 28, suggesting short-term mobilization of selenium transport proteins relevant to systemic selenium distribution and hepatic selenoprotein synthesis.
**Multi-Route Selenium Excretion Kinetics**
SeMSC produces approximately equal urinary and fecal selenium recovery plus measurable breath excretion (as volatile dimethylselenide), a disposal pattern distinct from selenomethionine and potentially advantageous in avoiding long-term tissue selenium loading.
**Plant-Derived Bioavailability in Functional Foods**
Consumption of SeMSC-enriched vegetables such as selenium-biofortified broccoli sprouts provides an organic, food-matrix selenium source with high bioavailability comparable to synthetic organic selenium supplements, supporting dietary strategies for selenium adequacy in selenium-deficient populations.
Origin & History
Natural habitat
Methylselenocysteine (SeMSC) is a naturally occurring selenoamino acid biosynthesized in selenium-hyperaccumulating and secondary-accumulating plant species including garlic (Allium sativum), onions (Allium cepa), broccoli (Brassica oleracea), and astragalus (Astragalus spp.), predominantly in selenium-enriched soils of regions such as the Great Plains of North America, parts of China, and volcanic soils globally. In plants, SeMSC accumulates preferentially in leaves and florets when roots are exposed to selenate concentrations of 20–75 µM, with optimal biosynthetic enzyme (BoSMT) induction occurring between 20–40 µM selenate. Unlike inorganic selenium or selenomethionine, SeMSC is a dedicated selenium storage and detoxification metabolite in these plants, not incorporated into structural proteins, which distinguishes its pharmacokinetic behavior from other dietary selenium forms.
“Methylselenocysteine does not have a documented history of deliberate use as an isolated compound in any traditional medicine system, as its chemical identity was not elucidated until the latter decades of the twentieth century. However, selenium-accumulating plants containing SeMSC—particularly garlic (Allium sativum) and astragalus (Astragalus membranaceus)—have extensive histories of medicinal use in Chinese, Ayurvedic, and Mediterranean traditional medicine, where their broad health-promoting effects were attributed to sulfur compounds, adaptogens, and immunomodulatory constituents rather than selenium chemistry specifically. Nutritional yeast products (including preparations sometimes called novexin protein concentrate or NPC yeast) have been historically associated with cancer-preventive dietary strategies in integrative oncology, and SeMSC has been proposed as one of the bioactive selenium species potentially responsible for observed effects, though this remains an inference rather than a demonstrated traditional formulation. The modern scientific characterization of SeMSC as a distinct bioactive selenoamino acid emerged primarily from agricultural selenium biofortification research in the 1990s–2000s, situating its recognized use firmly within contemporary nutritional science rather than ethnobotany.”Traditional Medicine
Scientific Research
The primary human pharmacokinetic evidence derives from a single randomized, double-blind, controlled crossover trial (n=29 selenium-replete healthy men, baseline plasma Se approximately 108 µg/L) that evaluated multiple doses of SeMSC (400 and 800 µg Se/day) against selenomethionine over 84 days, measuring plasma selenium, SEPP1, and excretion kinetics; this constitutes a small, well-designed but limited dataset that cannot support efficacy conclusions for chemoprevention endpoints. A separate single-dose pharmacokinetic study in the same research context evaluated 400, 800, and 1200 µg Se as SeMSC over 48 hours, demonstrating dose-dependent plasma selenium elevation with minimal differentiation between the 400 and 800 µg doses. No large-scale randomized controlled trials examining cancer incidence, cancer biomarkers, or other clinical endpoints have been completed using SeMSC as the isolated intervention; preclinical evidence in rodent mammary, colon, and prostate cancer models is more extensive but does not translate directly to established human efficacy. The overall clinical evidence base is sparse, consisting of one small pharmacokinetic RCT and preclinical mechanistic data, meaning SeMSC's chemopreventive potential in humans remains biologically plausible but clinically unverified.
Preparation & Dosage
Traditional preparation
**Synthetic Supplement Capsule/Tablet**
200–400 µg Se/day as SeMSC for general selenium adequacy support; doses of 400–800 µg Se/day studied in clinical pharmacokinetic research in replete adults.
**Single-Dose Pharmacokinetic Range**
400–1200 µg Se studied in single-dose trials; minimal plasma selenium differentiation observed between 400 and 800 µg in acute settings, suggesting diminishing returns above 400 µg for single doses.
**Selenium-Biofortified Vegetables (Functional Food)**
Broccoli sprouts or florets grown under 20–40 µM selenate conditions provide SeMSC in a food matrix; exact SeMSC content per serving varies by growing conditions but represents the most traditional dietary exposure route.
**Standardization**
Synthetic SeMSC supplements should be standardized to verified SeMSC content by HPLC-ICP-MS; food-derived sources are not standardized and selenium content varies widely by soil conditions.
**Timing**
No specific timing requirements established in clinical data; consistent daily dosing mirrors the study protocol that achieved measurable plasma selenium changes by day 28.
**Upper Limit Guidance**
The tolerable upper intake level for total selenium from all sources is 400 µg/day in adults (Institute of Medicine); supplemental SeMSC doses up to 800 µg Se/day have been administered in research without reported toxicity in replete subjects, but this exceeds general population UL guidance and should occur only under medical supervision.
Nutritional Profile
Methylselenocysteine is a low-molecular-weight selenoamino acid (C₄H₉NO₂Se, MW 182.08) and does not contribute meaningfully to macronutrient intake at supplemental doses. At a dose of 400 µg Se as SeMSC, the mass of compound administered is approximately 0.36 mg, contributing negligible calories, protein equivalents, or micronutrients beyond selenium itself. The compound is fully water-soluble and demonstrates high oral bioavailability comparable to selenomethionine, with selenium recovery distributed across urine, feces, and breath (as dimethylselenide); unlike selenomethionine, SeMSC-derived selenium is not stored in albumin or muscle protein, making its bioavailability profile functionally distinct despite similar total selenium absorption. In plant food sources, SeMSC co-occurs with glucosinolates (in Brassica species), allyl sulfur compounds (in Allium species), and other phytochemicals that may influence selenium absorption and metabolism; sulfate concentrations above 1 mM in the diet can competitively reduce plant SeMSC biosynthesis, suggesting that dietary sulfur-rich environments may modulate SeMSC availability from food sources.
How It Works
Mechanism of Action
SeMSC undergoes enzymatic cleavage by mammalian cysteine conjugate β-lyase (and related pyridoxal-5'-phosphate-dependent enzymes) to yield methylselenol (CH₃SeH), the primary proximate anticancer and bioactive metabolite; methylselenol can be further reduced to hydrogen selenide (H₂Se), a shared downstream metabolite in selenium metabolism that enters the selenide pool for selenoprotein biosynthesis or is excreted as dimethylselenide via the breath. At the molecular level, methylselenol has been shown in preclinical systems to activate caspase-dependent apoptotic pathways, downregulate cyclin-dependent kinase activity, inhibit VEGF-mediated angiogenic signaling, and reduce expression of anti-apoptotic proteins, collectively arresting tumor cell cycle progression. In contrast to selenomethionine, SeMSC is not a substrate for methionine tRNA synthetase and therefore cannot be misincorporated into proteins in place of methionine, which means selenium delivered via SeMSC is channeled exclusively through the metabolic selenium pool rather than sequestered in structural proteins. In plants, SeMSC biosynthesis is controlled by the enzyme selenocysteine methyltransferase (BoSMT in Brassica), which exhibits at least 40-fold higher substrate specificity for selenocysteine over cysteine and is transcriptionally upregulated by selenate but not by selenite or sulfate, with sulfate concentrations above 1 mM competitively inhibiting selenium incorporation.
Clinical Evidence
The pivotal human study was a randomized double-blind trial enrolling 29 selenium-replete adult men who received SeMSC at 400 or 800 µg Se/day or selenomethionine at equivalent doses for 84 days, with primary outcomes of plasma selenium concentration, SEPP1 (selenoprotein P), and selenium excretion patterns. SeMSC at 400 µg/day produced statistically significant plasma selenium increases by days 28 and 84, whereas the 800 µg/day dose paradoxically did not achieve sustained elevation, contrasting sharply with selenomethionine which doubled or tripled plasma selenium through progressive albumin-bound accumulation. SEPP1 showed only a transient peak on day 28 with SeMSC 800 µg/day without sustained elevation, indicating that SeMSC does not chronically upregulate selenium transport proteins to the degree selenomethionine does in already-replete individuals. These findings provide moderate confidence that SeMSC has a distinct, non-accumulative pharmacokinetic profile favorable for long-term supplementation safety, but the small sample size, exclusively male cohort, and absence of disease endpoints limit generalizability.
Safety & Interactions
In the primary clinical trial, SeMSC was well-tolerated in 29 selenium-replete adult men at doses up to 800 µg Se/day for 84 days with no severe adverse events reported; the non-accumulative plasma pharmacokinetics at this dose in replete subjects suggest a lower selenosis risk compared to equivalent selenomethionine doses, though the study was underpowered to detect rare adverse events. The tolerable upper intake level for selenium (all forms combined) established by the Institute of Medicine is 400 µg/day for adults; supplemental SeMSC doses used in research (400–1200 µg/day) exceed this threshold, and chronic use above the UL without medical supervision carries a theoretical risk of selenium toxicity symptoms including hair loss, nail brittleness, gastrointestinal disturbance, and peripheral neuropathy, though no such events were reported in available SeMSC-specific trials. No specific drug-drug interactions have been documented for SeMSC in the available literature; however, general selenium interactions warrant caution with anticoagulants (selenium may potentiate warfarin effects), chemotherapy agents (selenium status modulates drug metabolism and oxidative stress responses), and immunosuppressants. Safety in pregnancy and lactation has not been evaluated for supplemental SeMSC doses; the recommended dietary allowance for selenium in pregnancy is 60 µg/day and in lactation 70 µg/day, and supranutritional supplementation is not recommended in these populations without clinical indication.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
(2R)-2-amino-3-(methylselanyl)propanoic acidSe-methylselenocysteineSeMSCMSCmethyl selenocysteine
Frequently Asked Questions
What is methylselenocysteine and how is it different from selenomethionine?
Methylselenocysteine (SeMSC) is a naturally occurring selenoamino acid found in garlic, broccoli, and onions that is metabolized by β-lyase to methylselenol, an active anticancer selenium metabolite, rather than being incorporated into body proteins. Unlike selenomethionine, which is non-specifically stored in albumin and muscle proteins causing progressive plasma selenium accumulation, SeMSC does not accumulate in tissues, producing a safer pharmacokinetic profile at supranutritional doses—a difference confirmed in an 84-day clinical trial where selenomethionine doubled or tripled plasma selenium while SeMSC at 800 µg/day produced no significant long-term rise.
What dose of methylselenocysteine has been studied in human clinical trials?
Human pharmacokinetic studies have evaluated SeMSC at 400, 800, and 1200 µg selenium per day, with the most extensive data coming from an 84-day randomized double-blind trial using 400 and 800 µg Se/day in 29 selenium-replete adult men. The 400 µg/day dose produced statistically significant plasma selenium increases by days 28 and 84, while 800 µg/day paradoxically did not sustain elevation in already-replete subjects, suggesting that 400 µg/day may be the more pharmacokinetically active dose in populations with adequate baseline selenium status.
Is methylselenocysteine safe to take long-term?
In the primary clinical trial, SeMSC at up to 800 µg Se/day for 84 days was well-tolerated in selenium-replete men with no severe adverse effects reported, and its non-accumulative pharmacokinetics suggest lower selenosis risk than equivalent selenomethionine doses. However, these doses exceed the Institute of Medicine's tolerable upper intake level of 400 µg Se/day from all sources combined, and long-term safety beyond 84 days has not been formally studied; supplementation above 400 µg/day should therefore occur only under medical supervision with periodic plasma selenium monitoring.
Which foods are highest in methylselenocysteine?
SeMSC is found naturally in selenium-accumulating plants including garlic (Allium sativum), onions (Allium cepa), broccoli and broccoli sprouts (Brassica oleracea), and astragalus species, with concentrations dependent on soil selenium availability. Broccoli grown in selenate-enriched soil (20–40 µM selenate) shows highest SeMSC accumulation in florets and leaves after two or more weeks of exposure, and selenium biofortification of these crops is an active area of agricultural research aimed at increasing dietary SeMSC intake from food sources.
Does methylselenocysteine prevent cancer in humans?
No large-scale randomized controlled trial has tested SeMSC as an isolated intervention for cancer prevention endpoints in humans, so its chemopreventive efficacy in people is not established. Preclinical evidence in rodent models of mammary, colon, and prostate cancer is supportive, and the mechanism—β-lyase conversion to methylselenol, which induces apoptosis and inhibits angiogenesis—is biologically plausible, but the compound's cancer-protective role in humans currently remains a promising hypothesis requiring validation through clinical trials.
How is methylselenocysteine metabolized in the body differently than other selenium compounds?
Methylselenocysteine is uniquely converted by the enzyme β-lyase into methylselenol (CH₃SeH), a highly reactive selenium species that exerts direct anticancer effects independent of selenoprotein synthesis. This metabolic pathway allows methylselenocysteine to support both selenoprotein production for antioxidant defense and generate bioactive methylselenol for potential chemopreventive activity, distinguishing it from inorganic selenium forms that carry toxicity risks at higher doses.
Is methylselenocysteine effective for cancer prevention at supplemental doses studied in humans?
While preclinical studies demonstrate that methylselenol generated from methylselenocysteine inhibits cancer cell proliferation, induces apoptosis, and suppresses angiogenesis in laboratory models, evidence of cancer prevention efficacy in human clinical trials remains limited and mixed. Current research supports methylselenocysteine's potential as a chemopreventive agent, but dose-dependent clinical outcomes in humans have not been definitively established.
Who should consider methylselenocysteine supplementation and who should be cautious?
Individuals with inadequate dietary selenium intake, those at elevated oxidative stress risk, and potentially those with cancer prevention goals may benefit from methylselenocysteine supplementation due to its dual role in selenoprotein support and methylselenol generation. However, people with pre-existing kidney disease, those taking certain medications, and pregnant or nursing women should consult a healthcare provider first, as individual selenium status and metabolic capacity vary significantly.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w methylselenocysteine-se-methylselenocysteine curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
